Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from Sell
Fintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.
On October 7, 2026, the pre-action close was recorded at $2.54, which also represents the latest close. This price reflects a one-week price change of -3.61% from a baseline close of $2.63 on September 30, 2026. Over a longer timeframe, the stock experienced a one-month price change of -34.33% from its baseline close of $3.86 on September 4, 2026.
As of October 2, 2026, the current consensus target mean for Rocket Pharmaceuticals stood at $9.03, with a median target of $9.69. This mean target represents an implied change of +256.26% from the stock's trading levels. The prior consensus target mean was $9.02 on September 16, 2026, representing a consensus target revision of +0.15%. According to recommendation data from the period beginning September 1, 2026, the aggregate analyst sentiment consisted of 4 strong buy, 7 buy, 7 hold, 2 sell, and 0 strong sell recommendations. This distribution resulted in 55.0% positive, 35.0% hold, and 10.0% negative recommendations out of a total of 20. These figures remained unchanged from the prior recommendation period starting August 1, 2026.
Other financial institutions have also recently updated or reiterated their positions on the company. On October 7, 2026, Leerink Partners maintained its Market Perform rating, Wedbush reiterated its Outperform rating, and Chardan Capital maintained its Buy rating. Earlier, on September 16, 2026, Wedbush reiterated its Outperform rating, while Needham upgraded the stock from Hold to Buy. On September 15, 2026, Chardan Capital maintained its Buy rating.
Rocket Pharmaceuticals reported its latest earnings on August 10, 2026, posting an actual EPS of -0.48 compared to an estimated EPS of 0.2467, which represents an EPS surprise of -294.57%. The company reported actual revenue of $0.00 against an estimated revenue of $20,400,000.00. The upcoming earnings date is scheduled for November 5, 2026, during the after market close session. Rocket Pharmaceuticals, Inc., headquartered in the United States, is a biotechnology company specializing in the development of gene therapies for rare and devastating genetic diseases, targeting disorders such as Fanconi anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency using lentiviral and adeno-associated viral vectors.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 8, 2026 | Goldman Sachs | Sell | Neutral | upgrade |
| October 7, 2026 | Leerink Partners | Market Perform | Market Perform | maintained |
| October 7, 2026 | Wedbush | Outperform | Outperform | reiterated |
| October 7, 2026 | Chardan Capital | Buy | Buy | maintained |
| September 16, 2026 | Wedbush | Outperform | Outperform | reiterated |
| September 16, 2026 | Needham | Hold | Buy | upgrade |
| September 15, 2026 | Chardan Capital | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.